FLT3 and acute myeloid leukemia: This suggests that strategies promoting electron flux or targeting lipid metabolism, such as the PPARα agonist bezafibrate, known to increase mitochondrial mass and β-oxidation, may offer new therapeutic approaches for treating FLT3-mutated AML [93,94].